联化科技(002250) - 2025年9月2日至9月3日投资者关系活动记录表

Group 1: Financial Performance - In the first half of 2025, the company achieved significant profit growth compared to the same period last year, driven by cost reduction and efficiency improvements [1] - The increase in gross margin was attributed to enhanced capacity utilization in the plant protection business and product structure adjustments [1] - The pharmaceutical business experienced notable growth, primarily due to concentrated shipments, contributing to substantial exchange gains that further improved overall performance [1] Group 2: Pharmaceutical Business Developments - The pharmaceutical segment saw rapid revenue growth, supported by a strategy focused on major clients and partnerships with leading global pharmaceutical companies [2] - The company is actively expanding its client base and establishing stable commercial relationships with high-quality domestic and international clients [2] Group 3: UK Subsidiary Performance - The UK subsidiary showed significant improvement in operational performance, attributed to a stable supply chain and enhanced product delivery capabilities [3] - The subsidiary's capacity utilization increased, and it also benefited from considerable exchange gains in the first half of the year [3] Group 4: New Energy Projects - The company has achieved stable supply of electrolyte products and is gradually increasing production, with expectations for breakthrough revenue in the new energy sector in 2025 [4] - The new energy business aligns with the company's values and capabilities, positioning it for competitive advantage in a large market [4] Group 5: Solid-State Battery and Market Outlook - The company is monitoring industry trends and customer demands regarding solid-state battery development, focusing on product planning and innovation [5] - The company aims to optimize services and reduce costs to enhance competitiveness in the evolving battery market [5] Group 6: Competitive Landscape in India - Indian companies have entered the CDMO sector, primarily in the generic drug supply chain, but their competitiveness in the patented drug market remains unclear [6] - Despite lower costs in India, the company believes its comprehensive supply chain and mature waste management systems provide a competitive edge [6]